Illumina, Inc. (NASDAQ:ILMN) Shares Acquired by AIA Group Ltd

AIA Group Ltd boosted its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 67.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 25,829 shares of the life sciences company's stock after acquiring an additional 10,378 shares during the period. AIA Group Ltd's holdings in Illumina were worth $3,596,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. J.P. Morgan Private Wealth Advisors LLC bought a new stake in shares of Illumina during the 3rd quarter worth about $29,558,000. International Assets Investment Management LLC increased its position in Illumina by 210.5% during the 4th quarter. International Assets Investment Management LLC now owns 48,194 shares of the life sciences company's stock worth $6,711,000 after buying an additional 32,672 shares during the period. Aquila Investment Management LLC lifted its holdings in shares of Illumina by 150.0% during the fourth quarter. Aquila Investment Management LLC now owns 25,000 shares of the life sciences company's stock worth $3,481,000 after buying an additional 15,000 shares in the last quarter. Weil Company Inc. grew its stake in shares of Illumina by 59.2% in the third quarter. Weil Company Inc. now owns 22,963 shares of the life sciences company's stock valued at $3,152,000 after acquiring an additional 8,539 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Illumina by 15.0% during the third quarter. Vanguard Group Inc. now owns 17,967,758 shares of the life sciences company's stock worth $2,466,614,000 after acquiring an additional 2,336,935 shares during the period. Institutional investors and hedge funds own 89.42% of the company's stock.

Illumina Trading Down 1.4 %

Shares of Illumina stock traded down $1.60 during midday trading on Thursday, reaching $116.69. The company had a trading volume of 1,810,235 shares, compared to its average volume of 1,763,704. The firm has a market cap of $18.58 billion, a PE ratio of -15.90 and a beta of 1.19. The stock has a fifty day moving average price of $133.78 and a 200 day moving average price of $128.07. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.66 and a quick ratio of 1.29. Illumina, Inc. has a fifty-two week low of $89.00 and a fifty-two week high of $232.23.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, February 8th. The life sciences company reported $0.14 EPS for the quarter, beating analysts' consensus estimates of $0.01 by $0.13. The company had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.09 billion. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The company's quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.14 EPS. On average, equities analysts anticipate that Illumina, Inc. will post 0.91 earnings per share for the current year.

Insider Activity at Illumina

In related news, CEO Jacob Thaysen acquired 7,330 shares of the business's stock in a transaction dated Thursday, February 22nd. The shares were bought at an average price of $135.29 per share, with a total value of $991,675.70. Following the transaction, the chief executive officer now directly owns 14,861 shares of the company's stock, valued at $2,010,544.69. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.17% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

ILMN has been the topic of several recent research reports. TD Cowen cut shares of Illumina from an "outperform" rating to a "market perform" rating and set a $144.00 target price on the stock. in a report on Thursday, January 4th. OTR Global reaffirmed a "mixed" rating on shares of Illumina in a report on Wednesday, March 20th. HSBC lowered Illumina from a "buy" rating to a "hold" rating in a report on Tuesday, January 16th. Stephens reaffirmed an "overweight" rating and set a $170.00 price objective on shares of Illumina in a research report on Wednesday, April 10th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $253.00 price objective on shares of Illumina in a research note on Tuesday, April 9th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, Illumina currently has a consensus rating of "Hold" and an average price target of $167.70.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.